Viscosupplementation Devices Market Insights: Segment Analysis:
Viscosupplementation Devices Market By Product Type (SingleInjection, Three Injections, and Five Injections), By End-User (Hospitals,Orthopaedic Clinics, and Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Viscosupplementation Devices product segment, thesingle injection is expected to emerge as a foremost segment during theforecasted period. This is because single injection viscosupplementation products are relatively newer and are also cost-effective in comparison to already existing 3-5 injection viscosupplementation products.
Are you aware about Viscosupplementation Devices Competitive Landscape?
For instance, as per the study Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid published in the year 2017 by Estades-Rubio F.J. et al., a statistically significant improvement was observed for patients treated with single stabilized hyaluronic acid injection versus those who received standard hyaluronic acid in five injections.
Also, the study supports the use of single injection products in the treatment of knee OA and found a slight improvement in the economic impact on the healthcare system. Furthermore, rising investments by key players for improvingthe product portfolio to develop advanced products and to maintain marketposition is also a driving factor for the segmental growth of the viscosupplementation devices market. For instance, in March 2019, Seikagaku launched HyLink®, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy.
Learn more about Viscosupplementation Devices Market Forecast
North America is expected to dominate the overallViscosupplementation Devices Market:
North America is expected to dominate the overallViscosupplementation Devices market. This domination is owing to the favorablereimbursement scenario, advanced healthcare infrastructure, and developed research & development facilities in the region. For instance, In the United States, Orthovisc, Supartz Hyalgan, Synvisc, and other viscosupplementation products are approved by the FDA as Class III medical devices for the treatment of knee pain caused by osteoarthritis and are reimbursed by Medicaid, Medicare and other state health care programs.
Further, the rising prevalence of joint associated disorderssuch as arthritis and osteoarthritis among the population in the US is alsoanticipated to fuel the viscosupplementation market in the region.
According to the Center for Disease Control and Prevention (CDC) 2018, report about 43.5% (23.7million) of the 54.4 million adults were living witharthritis and with the aging of the US population, the prevalence of arthritis is expected to increase in the coming decades. In addition, the report also states that by the year 2040, an estimated 78.4 million (25.9% ofthe projected total adult population) adults aged 18 years and older will suffer from arthritis.
Also, as per the 2020 report of the Canadian Chronic DiseaseSurveillance System, approximately 3.9 million (13.6%) Canadians aged 20 yearsand older live with diagnosed osteoarthritis and 219,000 (8.7 per 1,000 persons per year) were newly diagnosed in 2016–2017. Therefore, the rising patient population in the region will increase the demand for such devices and will also fuel the market for viscosupplementation devices in the region.
Read more about Viscosupplementation Devices Market Companies
Latest Pharmaceuticals Reports by Delveinsight
